PTC Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 3 months.
- Its last 6 Sell calls were followed by roughly flat moves (+2%) three months out.
- Recent price momentum is -23.1% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 9.3% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation D-
How expensive the stock is versus earnings, sales and its own 5-year history.
| Forward P/E | 33.6x | Better than 14% |
| Price / Sales | 4.6x | Better than 25% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability B
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 97.3% | Better than 99% |
| Operating margin | 49.5% | Better than 98% |
| Net margin | 39.4% | Better than 95% |
| Return on equity | -216.7% | Better than 3% |
| Return on invested capital | -64.1% | Better than 4% |
Momentum C-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -19.2% | Better than 32% |
| 6-month return | -18.0% | Better than 29% |
| 12-month return (ex latest month) | -19.7% | Better than 15% |
| Distance below 52-week high | 37.9% | Better than 31% |
Financial Health C-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.3x | Better than 63% |
| Debt to assets | 93.4% | Better than 2% |
| Interest coverage | 5.6x | Better than 59% |
| Free cash flow / net income | 60.2% | Better than 18% |
Analyst View A-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 83.3% | Better than 63% |
| Upside to average target | 77.2% | Better than 78% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 58.33
- Open
- 58.78
- Day range
- 56.18 - 58.96
- Avg price
- 57.02
- Volume
- 952.60K
- Turnover
- 54.31M
- Turnover ratei
- 1.17%
- Volume ratioi
- 1.25
- Amplitudei
- 4.77%
- 52-week rangei
- 56.18 - 90.87
Valuation
- P/Ei
- 7.25
- P/E (TTM)i
- -42.42
- P/Bi
- -24.65
- EPSi
- 7.78
- Book value / shi
- -2.29
- Net profit
- 649.97M
- Net assets
- -191.23M
Share structure
- Market cap
- 4.71B
- Float capi
- 4.60B
- Shares out
- 83.54M
- Float sharesi
- 81.52M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
37.9% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-15.43M net over the window
Short interest
- Shares short
- 7.78M
- % of floati
- 9.31%
- Days to coveri
- 7.50
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of PTC Therapeutics (PTCT)?
PTC Therapeutics last traded at 56.42. This page shows a periodic quote snapshot. Check the displayed quote time.
What is PTC Therapeutics's market cap?
About 4.71B.
What is the P/E ratio of PTC Therapeutics?
The trailing twelve-month P/E is -42.42. The Valuation tab shows it against the stock's own five-year range.
Does PTC Therapeutics pay a dividend?
PTC Therapeutics does not currently pay a regular dividend.
Is PTC Therapeutics a buy according to analysts?
The consensus of 12 analysts is a Buy rating, with an average 12-month price target of 100.00, which implies 77.2% upside from the current price. This is not investment advice.
What is PTC Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates PTC Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
PTC Therapeutics discussion 0 comments